Who
John G. Stratton
Director
Company insider
Files Form 4 as: Director, Abbott Laboratories; Director, General Dynamics; Exec. Chairman of the Board, Frontier Communications Parent; EVP&Pres - Global Operations, Verizon Communications.
In numbers
- Trades disclosed
- 425
- Buys
- 4
- Sells
- 0
- Bought
- $1.2M
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 12 Jan 2007
- Last trade
- 30 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 2 Oct 2026 | ABT Abbott Laboratoriesoption or derivative · Biotechnology | SEC FORM 4 Code A | $39K397 at $98.83 | filing |
| 16 Sep 2026filed 18 Sep 2026 | GD General DynamicsAerospace & Defense | SEC FORM 4 Code A | $37K105 at $356.69 | filing |
| 16 Sep 2026filed 18 Sep 2026 | GD General DynamicsAerospace & Defense | SEC FORM 4 Code A | $37K105 at $356.69 | filing |
| 30 Jun 2026filed 1 Jul 2026 | ABT Abbott Laboratoriesoption or derivative · Biotechnology | SEC FORM 4 Code A | $39K432 at $90.74 | filing |
| 30 Jun 2026filed 1 Jul 2026 | ABT Abbott Laboratoriesoption or derivative · Biotechnology | SEC FORM 4 Code A | $39K432 at $90.74 | filing |
| 16 Jun 2026filed 18 Jun 2026 | GD General DynamicsAerospace & Defense | SEC FORM 4 Code A | $37K104 at $359.85 | filing |
| 16 Jun 2026filed 18 Jun 2026 | GD General DynamicsAerospace & Defense | SEC FORM 4 Code A | $37K104 at $359.85 | filing |
| 7 May 2026filed 18 Jun 2026 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Bought | $174K2,000 at $86.82 | filing |
| 7 May 2026filed 18 Jun 2026 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Bought | $174K2,000 at $86.82 | filing |
| 24 Apr 2026filed 28 Apr 2026 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Code A | —2,286 at $0.00 | filing |
| 24 Apr 2026filed 28 Apr 2026 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Code A | —2,286 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | ABT Abbott Laboratoriesoption or derivative · Biotechnology | SEC FORM 4 Code A | $39K382 at $102.67 | filing |
| 31 Mar 2026filed 2 Apr 2026 | ABT Abbott Laboratoriesoption or derivative · Biotechnology | SEC FORM 4 Code A | $39K382 at $102.67 | filing |
| 17 Mar 2026filed 19 Mar 2026 | GD General DynamicsAerospace & Defense | SEC FORM 4 Code A | $37K105 at $354.31 | filing |
| 17 Mar 2026filed 19 Mar 2026 | GD General DynamicsAerospace & Defense | SEC FORM 4 Code A | $37K105 at $354.31 | filing |
| 9 Mar 2026filed 11 Mar 2026 | GD General DynamicsAerospace & Defense | SEC FORM 4 Code F | $30K83 at $359.79 | filing |
| 9 Mar 2026filed 11 Mar 2026 | GD General DynamicsAerospace & Defense | SEC FORM 4 Code F | $30K83 at $359.79 | filing |
| 4 Mar 2026filed 6 Mar 2026 | GD General DynamicsAerospace & Defense | SEC FORM 4 Code A | —270 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | GD General Dynamicsoption or derivative · Aerospace & Defense | SEC FORM 4 Code A | —1,120 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | GD General Dynamicsoption or derivative · Aerospace & Defense | SEC FORM 4 Code A | —1,120 at $0.00 | filing |
News
Abbott Laboratories (NYSE:ABT) Given "Buy" Rating at TD CowenABT · dailypolitical.com · 16 Oct 2026Abbott Laboratories is More than a Dividend Stock. Here's Why.ABT · insidermonkey.com · 11 Oct 2026Barclays Initiates Coverage on Abbott Laboratories (NYSE:ABT)ABT · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name John G. Stratton; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.